Company Filing History:
2 out of 3,539 
2 out of 2,489 
Years Active: 2022-2024
Title: The Innovations of Robert Bailer
Introduction
Robert Bailer is an accomplished inventor based in Adamstown, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of neutralizing antibodies for HIV-1. With a total of two patents to his name, Bailer has focused on innovative solutions to combat this global health challenge.
Latest Patents
Bailer's latest patents include "10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use." This patent discloses neutralizing antibodies that specifically bind to HIV-1 Env, along with antigen binding fragments of these antibodies. It also provides nucleic acids encoding these antibodies, vectors, and host cells. Furthermore, methods for detecting HIV-1 using these antibodies are outlined. The patent emphasizes the use of these antibodies, antigen binding fragments, nucleic acids, and vectors to prevent and/or treat HIV-1 infections. Another significant patent is "Neutralizing antibodies to HIV-1 GP41 and their use," which shares similar innovations and applications in the fight against HIV-1.
Career Highlights
Throughout his career, Robert Bailer has worked with prestigious institutions such as the National Institutes of Health, a component of the US Department of Health & Human Services, and Columbia University. His work in these organizations has allowed him to contribute to groundbreaking research and advancements in the field of immunology.
Collaborations
Bailer has collaborated with notable colleagues, including Young Do Kwon and Ivelin Georgiev. These partnerships have further enhanced his research and development efforts in creating effective treatments for HIV-1.
Conclusion
Robert Bailer is a prominent inventor whose work in developing neutralizing antibodies for HIV-1 has the potential to make a significant impact on public health. His innovative patents and collaborations reflect his dedication to advancing medical science and improving treatment options for those affected by HIV-1.